Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 123 articles:
HTML format
Text format



Single Articles


    January 2017
  1. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    PubMed     Text format     Abstract available


  2. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    PubMed     Text format     Abstract available


  3. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    PubMed     Text format     Abstract available


    January 2016
  4. HONG H, Brown CE, Ostberg JR, Priceman SJ, et al
    L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
    PLoS One. 2016;11:e0146885.
    PubMed     Text format     Abstract available


  5. VIDAL F, Guerby P, Luyckx M, Haddad P, et al
    Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?
    PLoS One. 2016;11:e0147787.
    PubMed     Text format     Abstract available


  6. WILLIS S, Villalobos VM, Gevaert O, Abramovitz M, et al
    Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0149183.
    PubMed     Text format     Abstract available


  7. HUA X, Yu L, You R, Yang Y, et al
    Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis.
    PLoS One. 2016;11:e0151134.
    PubMed     Text format     Abstract available


  8. LEHTINEN L, Vesterkvist P, Roering P, Korpela T, et al
    REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.
    PLoS One. 2016;11:e0151590.
    PubMed     Text format     Abstract available


  9. XIA Y, Chang T, Wang Y, Liu Y, et al
    Correction: YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients.
    PLoS One. 2016;11:e0152712.
    PubMed     Text format     Abstract available


  10. RAHMAN MA, Ramli F, Karimian H, Dehghan F, et al
    Artonin E Induces Apoptosis via Mitochondrial Dysregulation in SKOV-3 Ovarian Cancer Cells.
    PLoS One. 2016;11:e0151466.
    PubMed     Text format     Abstract available


  11. ZUBERI M, Khan I, Mir R, Gandhi G, et al
    Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
    PLoS One. 2016;11:e0153902.
    PubMed     Text format     Abstract available


  12. CHOI JI, Park SH, Lee HJ, Lee DW, et al
    Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells.
    PLoS One. 2016;11:e0155052.
    PubMed     Text format     Abstract available


  13. ALAEE M, Danesh G, Pasdar M
    Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.
    PLoS One. 2016;11:e0154323.
    PubMed     Text format     Abstract available


  14. NORDIN N, Fadaeinasab M, Mohan S, Mohd Hashim N, et al
    Pulchrin A, a New Natural Coumarin Derivative of Enicosanthellum pulchrum, Induces Apoptosis in Ovarian Cancer Cells via Intrinsic Pathway.
    PLoS One. 2016;11:e0154023.
    PubMed     Text format     Abstract available


  15. PAINE MR, Kim J, Bennett RV, Parry RM, et al
    Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model.
    PLoS One. 2016;11:e0154837.
    PubMed     Text format     Abstract available


  16. MACLEAN JA 2ND, King ML, Okuda H, Hayashi K, et al
    WNT7A Regulation by miR-15b in Ovarian Cancer.
    PLoS One. 2016;11:e0156109.
    PubMed     Text format     Abstract available


  17. MARTIN SD, Brown SD, Wick DA, Nielsen JS, et al
    Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    PLoS One. 2016;11:e0155189.
    PubMed     Text format     Abstract available


  18. ZHOU Y, Xu X, Lv H, Wen Q, et al
    The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration.
    PLoS One. 2016;11:e0155250.
    PubMed     Text format     Abstract available


  19. FENG Z, Wen H, Bi R, Ju X, et al
    Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer.
    PLoS One. 2016;11:e0156101.
    PubMed     Text format     Abstract available


  20. SOSULSKI A, Horn H, Zhang L, Coletti C, et al
    CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
    PLoS One. 2016;11:e0156595.
    PubMed     Text format     Abstract available


  21. ZHOU Q, Li W, Leng B, Zheng W, et al
    Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0155495.
    PubMed     Text format     Abstract available


  22. TRACHANA SP, Pilalis E, Gavalas NG, Tzannis K, et al
    The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
    PLoS One. 2016;11:e0156403.
    PubMed     Text format     Abstract available


  23. BOTESTEANU DA, Lee JM, Levy D
    Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection.
    PLoS One. 2016;11:e0156661.
    PubMed     Text format     Abstract available


  24. HELLAND O, Popa M, Bischof K, Gjertsen BT, et al
    The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    PLoS One. 2016;11:e0158208.
    PubMed     Text format     Abstract available


  25. VIGORITO E, Kuchenbaecker KB, Beesley J, Adlard J, et al
    Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    PLoS One. 2016;11:e0158801.
    PubMed     Text format     Abstract available


  26. TAKAHASHI R, Mabuchi S, Kawano M, Sasano T, et al
    Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    PLoS One. 2016;11:e0151050.
    PubMed     Text format     Abstract available


  27. KIM HJ, Lee SY, Shin YR, Park CS, et al
    The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis.
    PLoS One. 2016;11:e0149465.
    PubMed     Text format     Abstract available


  28. YOSHIDA M, Taguchi A, Kawana K, Adachi K, et al
    Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    PLoS One. 2016;11:e0160330.
    PubMed     Text format     Abstract available


  29. CHOWANADISAI W, Messerli SM, Miller DH, Medina JE, et al
    Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
    PLoS One. 2016;11:e0151089.
    PubMed     Text format     Abstract available


  30. WANG T, Li W, Wu X, Yin B, et al
    Tubo-Ovarian Abscess (with/without Pseudotumor Area) Mimicking Ovarian Malignancy: Role of Diffusion-Weighted MR Imaging with Apparent Diffusion Coefficient Values.
    PLoS One. 2016;11:e0149318.
    PubMed     Text format     Abstract available


  31. PINTO P, Peixoto A, Santos C, Rocha P, et al
    Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
    PLoS One. 2016;11:e0161438.
    PubMed     Text format     Abstract available


  32. TALHOUK A, Kommoss S, Mackenzie R, Cheung M, et al
    Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.
    PLoS One. 2016;11:e0153844.
    PubMed     Text format     Abstract available


  33. SHAH JS, Soon PS, Marsh DJ
    Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs.
    PLoS One. 2016;11:e0153200.
    PubMed     Text format     Abstract available


  34. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    PubMed     Text format     Abstract available


  35. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    PubMed     Text format     Abstract available


  36. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    PubMed     Text format     Abstract available


  37. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    PubMed     Text format     Abstract available


  38. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    PubMed     Text format     Abstract available


  39. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    PubMed     Text format     Abstract available


  40. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    PubMed     Text format     Abstract available


  41. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    PubMed     Text format     Abstract available


  42. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    PubMed     Text format     Abstract available


  43. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    PubMed     Text format     Abstract available


  44. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    PubMed     Text format     Abstract available


    January 2015
  45. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2015;10:e0117654.
    PubMed     Text format     Abstract available


  46. ISOBE A, Sawada K, Kinose Y, Ohyagi-Hara C, et al
    Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer.
    PLoS One. 2015;10:e0118080.
    PubMed     Text format     Abstract available


  47. NAKAYAMA J, Raines TA, Lynch KR, Slack-Davis JK, et al
    Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1.
    PLoS One. 2015;10:e0120071.
    PubMed     Text format     Abstract available


  48. ZHOU Y, Liu Y, Li K, Zhang R, et al
    ICan: An Integrated Co-Alteration Network to Identify Ovarian Cancer-Related Genes.
    PLoS One. 2015;10:e0116095.
    PubMed     Text format     Abstract available


  49. WU J, Yin H, Zhu J, Buckanovich RJ, et al
    Validation of LRG1 as a Potential Biomarker for Detection of Epithelial Ovarian Cancer by a Blinded Study.
    PLoS One. 2015;10:e0121112.
    PubMed     Text format     Abstract available



  50. Correction: Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes.
    PLoS One. 2015;10:e0122284.
    PubMed     Text format     Abstract available


  51. LI L, Wang D, Zhou J, Cheng Y, et al
    Characteristics of Human Amniotic Fluid Mesenchymal Stem Cells and Their Tropism to Human Ovarian Cancer.
    PLoS One. 2015;10:e0123350.
    PubMed     Text format     Abstract available


  52. LI H, Wang D, Singh LS, Berk M, et al
    Correction: Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for Ovarian Cancer G Protein-Coupled Receptor 1.
    PLoS One. 2015;10:e0125463.
    PubMed     Text format     Abstract available


  53. SANKARANARAYANAN P, Schomay TE, Aiello KA, Alter O, et al
    Tensor GSVD of Patient- and Platform-Matched Tumor and Normal DNA Copy-Number Profiles Uncovers Chromosome Arm-Wide Patterns of Tumor-Exclusive Platform-Consistent Alterations Encoding for Cell Transformation and Predicting Ovarian Cancer Survival.
    PLoS One. 2015;10:e0121396.
    PubMed     Text format     Abstract available


  54. SETO KK, Andrulis IL
    Atypical Protein Kinase C Zeta: Potential Player in Cell Survival and Cell Migration of Ovarian Cancer.
    PLoS One. 2015;10:e0123528.
    PubMed     Text format     Abstract available


  55. PAI HC, Kumar S, Shen CC, Liou JP, et al
    MT-4 Suppresses Resistant Ovarian Cancer Growth through Targeting Tubulin and HSP27.
    PLoS One. 2015;10:e0123819.
    PubMed     Text format     Abstract available


  56. MA Y, Zhang X, Xu X, Shen L, et al
    STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0124924.
    PubMed     Text format     Abstract available


  57. HU ZD, Wei TT, Yang M, Ma N, et al
    Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review.
    PLoS One. 2015;10:e0126444.
    PubMed     Text format     Abstract available


  58. LI N, Yang L, Wang H, Yi T, et al
    MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    PLoS One. 2015;10:e0128886.
    PubMed     Text format     Abstract available


  59. JANATOVA M, Soukupova J, Stribrna J, Kleiblova P, et al
    Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    PLoS One. 2015;10:e0127711.
    PubMed     Text format     Abstract available


  60. KWIATKOWSKI F, Arbre M, Bidet Y, Laquet C, et al
    BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
    PLoS One. 2015;10:e0127363.
    PubMed     Text format     Abstract available


  61. CHORNOKUR G, Lin HY, Tyrer JP, Lawrenson K, et al
    Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
    PLoS One. 2015;10:e0128106.
    PubMed     Text format     Abstract available


  62. LANG F, Qin Z, Li F, Zhang H, et al
    Apoptotic Cell Death Induced by Resveratrol Is Partially Mediated by the Autophagy Pathway in Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0129196.
    PubMed     Text format     Abstract available


  63. TUMMERS QR, Hoogstins CE, Peters AA, de Kroon CD, et al
    The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer.
    PLoS One. 2015;10:e0129766.
    PubMed     Text format     Abstract available


  64. RAVOORI MK, Nishimura M, Singh SP, Lu C, et al
    Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
    PLoS One. 2015;10:e0131095.
    PubMed     Text format     Abstract available


  65. DU Y, Feng J, Wang R, Zhang H, et al
    Effects of Flavonoids from Potamogeton crispus L. on Proliferation, Migration, and Invasion of Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0130685.
    PubMed     Text format     Abstract available


  66. ZHOU Y, Bian B, Yuan X, Xie G, et al
    Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2015;10:e0130873.
    PubMed     Text format     Abstract available


  67. QIN DJ, Tang CX, Yang L, Lei H, et al
    Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells.
    PLoS One. 2015;10:e0132337.
    PubMed     Text format     Abstract available


  68. BOBBS A, Gellerman K, Hallas WM, Joseph S, et al
    ARID3B Directly Regulates Ovarian Cancer Promoting Genes.
    PLoS One. 2015;10:e0131961.
    PubMed     Text format     Abstract available


  69. MO L, Pospichalova V, Huang Z, Murphy SK, et al
    Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0131579.
    PubMed     Text format     Abstract available


  70. ZHANG S, Lu Z, Mao W, Ahmed AA, et al
    CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
    PLoS One. 2015;10:e0131833.
    PubMed     Text format     Abstract available


  71. HARAGUCHI M, Sato M, Ozawa M
    CRISPR/Cas9n-Mediated Deletion of the Snail 1Gene (SNAI1) Reveals Its Role in Regulating Cell Morphology, Cell-Cell Interactions, and Gene Expression in Ovarian Cancer (RMG-1) Cells.
    PLoS One. 2015;10:e0132260.
    PubMed     Text format     Abstract available


  72. LEE YC, Lee CH, Tsai HP, An HW, et al
    Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
    PLoS One. 2015;10:e0132579.
    PubMed     Text format     Abstract available


  73. CHAO A, Tsai CL, Jung SM, Chuang WC, et al
    BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.
    PLoS One. 2015;10:e0133081.
    PubMed     Text format     Abstract available


  74. NIU L, Li S, Liang H, Li H, et al
    The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
    PLoS One. 2015;10:e0135822.
    PubMed     Text format     Abstract available


  75. BELOTTE J, Fletcher NM, Saed MG, Abusamaan MS, et al
    A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
    PLoS One. 2015;10:e0135739.
    PubMed     Text format     Abstract available


  76. GRANADOS ML, Hudson LG, Samudio-Ruiz SL
    Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0136893.
    PubMed     Text format     Abstract available


  77. QIAN X, Qin J, Pan S, Li X, et al
    Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0139026.
    PubMed     Text format     Abstract available


  78. YUAN C, Liu X, Liu X, Yang N, et al
    The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.
    PLoS One. 2015;10:e0138692.
    PubMed     Text format     Abstract available


  79. DEVAPATLA B, Sharma A, Woo S
    CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PLoS One. 2015;10:e0139237.
    PubMed     Text format     Abstract available


  80. AUST S, Knogler T, Pils D, Obermayr E, et al
    Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0140403.
    PubMed     Text format     Abstract available


  81. GARZIERA M, Montico M, Bidoli E, Scalone S, et al
    Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
    PLoS One. 2015;10:e0140351.
    PubMed     Text format     Abstract available


  82. BENSON EA, Skaar TC, Liu Y, Nephew KP, et al
    Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    PLoS One. 2015;10:e0141279.
    PubMed     Text format     Abstract available


  83. LIU J, Bai J, Jiang G, Li X, et al
    Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration.
    PLoS One. 2015;10:e0142157.
    PubMed     Text format     Abstract available


  84. CHAO WR, Lee MY, Ruan A, Sheng HP, et al
    Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    PLoS One. 2015;10:e0142135.
    PubMed     Text format     Abstract available


  85. WU N, Wei J, Wang Y, Yan J, et al
    Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.
    PLoS One. 2015;10:e0143659.
    PubMed     Text format     Abstract available


  86. PATHAK HB, Zhou Y, Sethi G, Hirst J, et al
    A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0144126.
    PubMed     Text format     Abstract available


  87. QIAO JJ, Yu J, Yu Z, Li N, et al
    Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.
    PLoS One. 2015;10:e0118872.
    PubMed     Text format     Abstract available


  88. MISHRA EK, Corcoran JP, Hallifax RJ, Stradling J, et al
    Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions.
    PLoS One. 2015;10:e0123798.
    PubMed     Text format     Abstract available


  89. VERMEERSCH KA, Wang L, Mezencev R, McDonald JF, et al
    OVCAR-3 spheroid-derived cells display distinct metabolic profiles.
    PLoS One. 2015;10:e0118262.
    PubMed     Text format     Abstract available


  90. EULENBURG C, Mahner S, Woelber L, Wegscheider K, et al
    A systematic model specification procedure for an illness-death model without recovery.
    PLoS One. 2015;10:e0123489.
    PubMed     Text format     Abstract available


  91. RAO TD, Tian H, Ma X, Yan X, et al
    Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    PLoS One. 2015;10:e0126633.
    PubMed     Text format     Abstract available


  92. GLASER G, Weroha SJ, Becker MA, Hou X, et al
    Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    PLoS One. 2015;10:e0126867.
    PubMed     Text format     Abstract available


  93. CHEN S, Chen X, Xiu YL, Sun KX, et al
    Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    PLoS One. 2015;10:e0125714.
    PubMed     Text format     Abstract available


  94. WANG X, Jiang P, Wang P, Yang CS, et al
    EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
    PLoS One. 2015;10:e0125402.
    PubMed     Text format     Abstract available


  95. KANG J, Lee HJ, Kim J, Lee JJ, et al
    Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
    PLoS One. 2015;10:e0118927.
    PubMed     Text format     Abstract available


  96. LINDEGREN S, Andrade LN, Back T, Machado CM, et al
    Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
    PLoS One. 2015;10:e0126298.
    PubMed     Text format     Abstract available


  97. YE S, Yang J, Cao D, Bai H, et al
    Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
    PLoS One. 2015;10:e0121818.
    PubMed     Text format     Abstract available


  98. PATTERSON SD, Rossi JM, Paweletz KL, Fitzpatrick VD, et al
    Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
    PLoS One. 2015;10:e0122149.
    PubMed     Text format     Abstract available


  99. DE BOER E, Crane LM, van Oosten M, van der Vegt B, et al
    Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.
    PLoS One. 2015;10:e0135012.
    PubMed     Text format     Abstract available


  100. SCHUMMER M, Thorpe J, Giraldez M, Bergan L, et al
    Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    PLoS One. 2015;10:e0142911.
    PubMed     Text format     Abstract available


  101. KENMOGNE LC, Ayan D, Roy J, Maltais R, et al
    The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers.
    PLoS One. 2015;10:e0144890.
    PubMed     Text format     Abstract available


    January 2014
  102. YAMAGUCHI S, Maida Y, Yasukawa M, Kato T, et al
    Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.
    PLoS One. 2014;9:e112438.
    PubMed     Text format     Abstract available


  103. XIA Y, Zhang YL, Yu C, Chang T, et al
    YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells.
    PLoS One. 2014;9:e109575.
    PubMed     Text format     Abstract available


  104. ZHAO F, Siu MK, Jiang L, Tam KF, et al
    Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance.
    PLoS One. 2014;9:e113478.
    PubMed     Text format     Abstract available


  105. HAYANO T, Yokota Y, Hosomichi K, Nakaoka H, et al
    Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer.
    PLoS One. 2014;9:e114491.
    PubMed     Text format     Abstract available


  106. ZHANG S, Yuan Y, Hao D
    A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy.
    PLoS One. 2014;9:e113169.
    PubMed     Text format     Abstract available


  107. PANDYA D, Mariani M, McHugh M, Andreoli M, et al
    Herpes Virus MicroRNA Expression and Significance in Serous Ovarian Cancer.
    PLoS One. 2014;9:e114750.
    PubMed     Text format     Abstract available


  108. KASHIYAMA T, Oda K, Ikeda Y, Shiose Y, et al
    Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    PLoS One. 2014;9:e87220.
    PubMed     Text format     Abstract available


  109. CHENG FH, Aguda BD, Tsai JC, Kochanczyk M, et al
    A Mathematical Model of Bimodal Epigenetic Control of miR-193a in Ovarian Cancer Stem Cells.
    PLoS One. 2014;9:e116050.
    PubMed     Text format     Abstract available



  110. Correction: Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway.
    PLoS One. 2014;9:e116447.
    PubMed     Text format     Abstract available


  111. KWAK Y, Lee HE, Kim WH, Kim DW, et al
    The clinical implication of cancer-associated microvasculature and fibroblast in advanced colorectal cancer patients with synchronous or metachronous metastases.
    PLoS One. 2014;9:e91811.
    PubMed     Text format     Abstract available


  112. ALQUMBER MA, Akhter N, Haque S, Panda AK, et al
    Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis.
    PLoS One. 2014;9:e94874.
    PubMed     Text format     Abstract available


  113. BRODSKY AS, Fischer A, Miller DH, Vang S, et al
    Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease.
    PLoS One. 2014;9:e94476.
    PubMed     Text format     Abstract available


  114. GAO Q, Chen C, Ji T, Wu P, et al
    A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.
    PLoS One. 2014;9:e94050.
    PubMed     Text format     Abstract available


  115. CALECA L, Putignano AL, Colombo M, Congregati C, et al
    Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
    PLoS One. 2014;9:e86924.
    PubMed     Text format     Abstract available


  116. CHO H, Cho CS, Indig GL, Lavasanifar A, et al
    Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance.
    PLoS One. 2014;9:e89968.
    PubMed     Text format     Abstract available


  117. YAKUBOV B, Chen L, Belkin AM, Zhang S, et al
    Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
    PLoS One. 2014;9:e89285.
    PubMed     Text format     Abstract available


  118. CARAZZOLLE MF, de Carvalho LM, Slepicka HH, Vidal RO, et al
    IIS--Integrated Interactome System: a web-based platform for the annotation, analysis and visualization of protein-metabolite-gene-drug interactions by integrating a variety of data sources and tools.
    PLoS One. 2014;9:e100385.
    PubMed     Text format     Abstract available


  119. HELLAND O, Popa M, Vintermyr OK, Molven A, et al
    First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.
    PLoS One. 2014;9:e89527.
    PubMed     Text format     Abstract available


  120. GLEICHER N, McAlpine JN, Gilks CB, Kushnir VA, et al
    Absence of BRCA/FMR1 correlations in women with ovarian cancers.
    PLoS One. 2014;9:e102370.
    PubMed     Text format     Abstract available


  121. VIZCAINO C, Nunez LE, Moris F, Portugal J, et al
    Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.
    PLoS One. 2014;9:e104687.
    PubMed     Text format     Abstract available


  122. SINHA S, Tsang EK, Zeng H, Meister M, et al
    Mining TCGA data using Boolean implications.
    PLoS One. 2014;9:e102119.
    PubMed     Text format     Abstract available


  123. JONSSON JM, Johansson I, Dominguez-Valentin M, Kimbung S, et al
    Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    PLoS One. 2014;9:e107643.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: